RVLP News and Press, RVL Pharmaceuticals plc From 05/12/22

First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 Reaffirms fourth quarter 2...

UPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards" PR Newswire BRIDGEWATER, N.J. , May 9, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company") announced toda...

BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a commercia...

UPNEEQ® Wins "Best in Innovation" Award from New Beauty PR Newswire 12th Annual Beauty Awards Selected from over 10,000 Entrants BRIDGEWATER, N.J. , April 6, 2022 /PRNewswire/ -- RVL Pharmaceuticals plc (Nasdaq: RVLP) announced today that its U.S...

RVL Pharmaceuticals (NASDAQ:RVLP) said preliminary Q1 2022 net product sales of eye drug Upneeq is $5.9M. On March 30, the company said it expected Upneeq sales to be in the range of $5.5M to 6M, while reporting its Q4 results. Upneeq (oxymetazoline hydrochloride ophthalmic solution...

-- Expects first quarter 2022 preliminary UPNEEQ net product sales of approximately $5.9 million, representing an increase of 90% from the fourth quarter 2021 -- -- Reaffirms fourth quarter 2022 guidance of $20 to 25 million in UPNEEQ net product sales -- -- UPNEEQ selected as the...

RVL Pharmaceuticals plc (RVLP) Q4 2021 Earnings Conference Call March 30, 2022, 4:30 PM ET Company Participants Brian Markison – Chief Executive Officer Andrew Einhorn – Chief Financial Officer JD Schaub – Chief Operating Officer Lisa Wilson – Investor Relations Co...

press release (NASDAQ:RVLP): Q4 net loss of $19.7M Revenue of $2.9M (+163.6% Y/Y) misses by $0.2M. For further details see: reports Q4 results

Fourth quarter 2021 UPNEEQ product sales of $3.1 million, representing 39% growth over third quarter sales Fourth quarter and full year 2021 total revenues of $2.9 million and $17.5 million, respectively Full national launch of UPNEEQ into medical aesthetics market in Febr...

Hapless Osmotica renamed itself RVL Pharmaceuticals. It has a novel business model which vastly simplifies its business. Encouragingly, recent company estimate pegs 2022 Q4 UPNEEQ net revenues at $20-$25 million. For further details see: RVL Pharmaceuticals: A Makeover F...